Loading...
•
Sep 30, 2024
Avadel Q3 2024 Earnings Report
Announced third quarter financial results and provided a corporate update.
Key Takeaways
Avadel Pharmaceuticals reported $50.0 million in net product revenue for the third quarter 2024, driven by sales of LUMRYZ. The company also received FDA approval for LUMRYZ for pediatric narcolepsy and saw a court uphold the FDA's determination that LUMRYZ is clinically superior to twice-nightly oxybate products. They had 2,300 patients on LUMRYZ as of September 30th, including 700 patients that initiated therapy in the quarter.
Generated $50.0 million in net revenue from sales of LUMRYZ™.
Had 2,300 patients on LUMRYZ as of September 30th, including 700 patients that initiated therapy in the quarter.
Received FDA approval for LUMRYZ for the treatment of cataplexy or EDS in patients 7 years and older with narcolepsy.
LUMRYZ approval upheld by court in suit brought by Jazz regarding FDA’s determination that LUMRYZ is clinically superior to twice-nightly oxybate products.
Avadel
Avadel
Avadel Revenue by Segment
Revenue by Segment
LUMRYZ Net Product Revenue
CapyFin.com Forward Guidance
Avadel is focused on expanding the oxybate market through the introduction of LUMRYZ, expanding into additional patient populations, and continuing the Phase 3 pivotal trial in IH.
Positive Outlook
- Potential therapeutic benefit of LUMRYZ
- Success of the commercialization of LUMRYZ and expansion into additional patient populations
- Anticipated market demand and sales opportunity of LUMRYZ
- Potential for the Company to be a leader in the market
- Advancing the Company’s idiopathic hypersomnia clinical study for LUMRYZ
Challenges Ahead
- Risks and uncertainties described in the “Risk Factors” section of Part I, Item 1A of the Company’s most recent Annual Report on Form 10-K
- Competition in the market
- Potential delays in clinical trials
- Changes in regulations
- Unfavorable outcomes in legal proceedings